Tempus AI Inc (NASDAQ:TEM) stock is trading marginally lower on Monday, showing little movement after a 7% gain last week. On Friday, HC Wainwright & Co. analyst Yi Chen reiterated a Buy rating on the artificial intelligence and precision medicine company, raising the price target to $98 from $90.
What To Know: The company recently received 510(k) clearance from the U.S. Food and Drug Administration for its updated Tempus Pixel, an AI-powered cardiac imaging platform. The update enhances the device’s cardiac MR imaging analysis capabilities by allowing the generation of T1 and T2 inline maps directly from raw MRI data.
